JP2018141025A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018141025A5 JP2018141025A5 JP2018118937A JP2018118937A JP2018141025A5 JP 2018141025 A5 JP2018141025 A5 JP 2018141025A5 JP 2018118937 A JP2018118937 A JP 2018118937A JP 2018118937 A JP2018118937 A JP 2018118937A JP 2018141025 A5 JP2018141025 A5 JP 2018141025A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- composition according
- dose
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022144425A JP7581292B2 (ja) | 2017-01-31 | 2022-09-12 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
| JP2024190237A JP2025016617A (ja) | 2017-01-31 | 2024-10-30 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201700775YA SG10201700775YA (en) | 2017-01-31 | 2017-01-31 | A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease |
| SG10201700775Y | 2017-01-31 | ||
| SG10201705954VA SG10201705954VA (en) | 2017-07-20 | 2017-07-20 | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
| SG10201705954V | 2017-07-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018014743A Division JP6383122B2 (ja) | 2017-01-31 | 2018-01-31 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022144425A Division JP7581292B2 (ja) | 2017-01-31 | 2022-09-12 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018141025A JP2018141025A (ja) | 2018-09-13 |
| JP2018141025A5 true JP2018141025A5 (enExample) | 2021-03-11 |
| JP7141865B2 JP7141865B2 (ja) | 2022-09-26 |
Family
ID=61617058
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018014743A Active JP6383122B2 (ja) | 2017-01-31 | 2018-01-31 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
| JP2018118937A Active JP7141865B2 (ja) | 2017-01-31 | 2018-06-22 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
| JP2022144425A Active JP7581292B2 (ja) | 2017-01-31 | 2022-09-12 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
| JP2024190237A Pending JP2025016617A (ja) | 2017-01-31 | 2024-10-30 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018014743A Active JP6383122B2 (ja) | 2017-01-31 | 2018-01-31 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022144425A Active JP7581292B2 (ja) | 2017-01-31 | 2022-09-12 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
| JP2024190237A Pending JP2025016617A (ja) | 2017-01-31 | 2024-10-30 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20190367599A1 (enExample) |
| EP (2) | EP3577135B1 (enExample) |
| JP (4) | JP6383122B2 (enExample) |
| KR (4) | KR102365871B1 (enExample) |
| CN (1) | CN110167961A (enExample) |
| AU (2) | AU2018215039B2 (enExample) |
| BR (1) | BR112019015426A2 (enExample) |
| CA (1) | CA3051389A1 (enExample) |
| CR (2) | CR20190403A (enExample) |
| ES (1) | ES2947735T3 (enExample) |
| IL (2) | IL307593A (enExample) |
| MX (2) | MX2019007749A (enExample) |
| MY (1) | MY201148A (enExample) |
| NZ (1) | NZ756629A (enExample) |
| PH (1) | PH12019501706A1 (enExample) |
| PL (1) | PL3577135T3 (enExample) |
| SG (2) | SG10201908697XA (enExample) |
| TW (3) | TW202412841A (enExample) |
| UA (1) | UA129282C2 (enExample) |
| WO (1) | WO2018143266A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| PT2708559T (pt) | 2008-04-11 | 2018-05-16 | Chugai Pharmaceutical Co Ltd | Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| HUE056489T2 (hu) | 2014-12-19 | 2022-02-28 | Chugai Pharmaceutical Co Ltd | Anti-C5 antitestek és alkalmazási eljárások |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| JP2019517473A (ja) | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 難治性全身型重症筋無力症の処置のための方法 |
| MY191668A (en) | 2016-06-14 | 2022-07-06 | Regeneron Pharma | Anti-c5 antibodies and uses thereof |
| KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| KR20200070355A (ko) * | 2017-10-26 | 2020-06-17 | 알렉시온 파마슈티칼스, 인코포레이티드 | 발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여 |
| JP2021506241A (ja) | 2017-12-13 | 2021-02-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗ｃ５抗体組み合わせ物およびその使用 |
| EP3802603A1 (en) | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
| US12240893B2 (en) * | 2018-10-30 | 2025-03-04 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) |
| CN114929273A (zh) * | 2019-07-31 | 2022-08-19 | 豪夫迈·罗氏有限公司 | 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案 |
| AU2020319677A1 (en) * | 2019-07-31 | 2022-01-06 | F. Hoffmann-La Roche Ag | Dosage and administration regimen for the treatment or prevention of C5-related diseases by the use of the anti-C5 antibody Crovalimab |
| WO2021081277A1 (en) * | 2019-10-25 | 2021-04-29 | Regeneron Pharmaceuticals, Inc. | Dosing regimens for treating or preventing c5-associated diseases |
| CA3196434A1 (en) * | 2020-10-23 | 2022-04-28 | Krista K. JOHNSON | Methods of treating patients having complement disorders using anti-c5 antibodies |
| JP2024060738A (ja) | 2022-10-20 | 2024-05-07 | セイコーエプソン株式会社 | 気体分離膜 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| DE69937291T2 (de) | 1998-04-02 | 2008-07-10 | Genentech, Inc., South San Francisco | Antikörpervarianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU2001296594A1 (en) | 2000-10-10 | 2002-04-22 | Tanox, Inc. | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| US7432356B2 (en) | 2001-08-17 | 2008-10-07 | Genentech, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| PT1572744E (pt) | 2002-12-16 | 2010-09-07 | Genentech Inc | Variantes de imunoglobulina e utilizações destas |
| US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| BR122019012028B1 (pt) | 2004-04-13 | 2023-09-26 | F. Hoffmann-La Roche Ag | Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| DK2359834T5 (en) | 2006-03-15 | 2017-02-06 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor |
| PT2708559T (pt) | 2008-04-11 | 2018-05-16 | Chugai Pharmaceutical Co Ltd | Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio |
| WO2010015608A1 (en) | 2008-08-05 | 2010-02-11 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c5 |
| RS64039B1 (sr) | 2008-11-10 | 2023-04-28 | Alexion Pharma Inc | Metode i kompozicije za lečenje poremećaja povezanih sa komplementom |
| CN105218674A (zh) | 2010-03-11 | 2016-01-06 | 瑞纳神经科学公司 | 呈pH依赖性抗原结合的抗体 |
| TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| PL2970974T3 (pl) * | 2013-03-14 | 2018-01-31 | Alnylam Pharmaceuticals Inc | Kompozycje komponentu C5 dopełniacza iRNA i sposoby ich zastosowania |
| WO2014160958A1 (en) * | 2013-03-29 | 2014-10-02 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| HUE056489T2 (hu) * | 2014-12-19 | 2022-02-28 | Chugai Pharmaceutical Co Ltd | Anti-C5 antitestek és alkalmazási eljárások |
| US20180142010A1 (en) * | 2015-06-26 | 2018-05-24 | Alexion Pharmaceuticals, Inc. | Method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| US20190023775A1 (en) | 2016-01-11 | 2019-01-24 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| WO2017132259A1 (en) | 2016-01-25 | 2017-08-03 | Shire Human Genetic Therapies, Inc. | Anti-c5 antibodies with enhanced ph switch |
-
2018
- 2018-01-31 CN CN201880005975.XA patent/CN110167961A/zh active Pending
- 2018-01-31 MX MX2019007749A patent/MX2019007749A/es unknown
- 2018-01-31 WO PCT/JP2018/003193 patent/WO2018143266A1/en not_active Ceased
- 2018-01-31 NZ NZ756629A patent/NZ756629A/en unknown
- 2018-01-31 KR KR1020197004219A patent/KR102365871B1/ko active Active
- 2018-01-31 TW TW112148241A patent/TW202412841A/zh unknown
- 2018-01-31 CR CR20190403A patent/CR20190403A/es unknown
- 2018-01-31 KR KR1020227005327A patent/KR102514175B1/ko active Active
- 2018-01-31 US US16/480,047 patent/US20190367599A1/en not_active Abandoned
- 2018-01-31 IL IL307593A patent/IL307593A/en unknown
- 2018-01-31 TW TW107103450A patent/TWI658834B/zh active
- 2018-01-31 TW TW108110617A patent/TWI828672B/zh active
- 2018-01-31 KR KR1020187009861A patent/KR101949891B1/ko active Active
- 2018-01-31 SG SG10201908697X patent/SG10201908697XA/en unknown
- 2018-01-31 PL PL18710159.7T patent/PL3577135T3/pl unknown
- 2018-01-31 KR KR1020237009640A patent/KR20230043247A/ko not_active Ceased
- 2018-01-31 CA CA3051389A patent/CA3051389A1/en active Pending
- 2018-01-31 JP JP2018014743A patent/JP6383122B2/ja active Active
- 2018-01-31 EP EP18710159.7A patent/EP3577135B1/en active Active
- 2018-01-31 UA UAA201909498A patent/UA129282C2/uk unknown
- 2018-01-31 MY MYPI2019004320A patent/MY201148A/en unknown
- 2018-01-31 CR CR20220563A patent/CR20220563A/es unknown
- 2018-01-31 BR BR112019015426-4A patent/BR112019015426A2/pt unknown
- 2018-01-31 EP EP23165354.4A patent/EP4223774A3/en active Pending
- 2018-01-31 IL IL268327A patent/IL268327B2/en unknown
- 2018-01-31 SG SG11201801401UA patent/SG11201801401UA/en unknown
- 2018-01-31 AU AU2018215039A patent/AU2018215039B2/en active Active
- 2018-01-31 ES ES18710159T patent/ES2947735T3/es active Active
- 2018-06-22 JP JP2018118937A patent/JP7141865B2/ja active Active
-
2019
- 2019-06-26 MX MX2022012931A patent/MX2022012931A/es unknown
- 2019-07-24 PH PH12019501706A patent/PH12019501706A1/en unknown
-
2020
- 2020-07-14 US US16/928,129 patent/US20200407432A1/en not_active Abandoned
-
2022
- 2022-09-12 JP JP2022144425A patent/JP7581292B2/ja active Active
-
2023
- 2023-03-10 US US18/181,641 patent/US20230250162A1/en active Pending
-
2024
- 2024-08-23 AU AU2024216280A patent/AU2024216280A1/en not_active Abandoned
- 2024-10-30 JP JP2024190237A patent/JP2025016617A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018141025A5 (enExample) | ||
| KR102365871B1 (ko) | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 | |
| US9636334B2 (en) | Combination of lenalidomide and polypeptide construct, and uses thereof | |
| AU2019305857B2 (en) | Drug combination of quinoline derivative and antibody | |
| ES2783448T3 (es) | Métodos de tratamiento del lupus eritematoso sistémico utilizando un anticuerpo de dominio dirigido contra CD28 | |
| JP6672516B2 (ja) | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 | |
| JP2005516917A (ja) | 細胞外アデノシン阻害剤およびアデノシン受容体阻害剤を用いて免疫応答および炎症を増強するための方法 | |
| KR102321372B1 (ko) | 인터류킨-6에 대한 항체 및 그의 용도 | |
| JP2020019769A5 (enExample) | ||
| US20140120094A1 (en) | Use of IL-20 Antagonists for Treating Liver Diseases | |
| KR20160079918A (ko) | Ｖｅｇｆ 억제제 및 이리노테칸을 함유하는 항종양 조합물 | |
| US11014973B2 (en) | Fusion proteins for treating cancer and related methods | |
| WO2021213523A1 (zh) | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 | |
| JP2022104920A5 (enExample) | ||
| JP2020150947A (ja) | 抗ポドプラニン抗体 | |
| US9982043B2 (en) | Use of IL-20 antagonists for treating pancreatic cancer | |
| JP2022101535A5 (enExample) | ||
| Moss | Mechanism of action and pharmacokinetics of biologics | |
| US9751949B2 (en) | Method of inhibiting adipogenesis with an IL-20 antibody | |
| US12409208B2 (en) | Treating tissue fibrosis with interleukin 24 | |
| RU2022103727A (ru) | Дозировка и схема введения для лечения или предупреждения связанных с с5 заболеваний посредством применения антитела против с5 кровалимаба | |
| WO2025113598A1 (zh) | 稳定的混合抗体的药物组合物 | |
| RU2022103731A (ru) | Дозировка и схема введения для лечения или предупреждения связанных с с5 заболеваний посредством применения антитела против с5 кровалимаба | |
| WO2016164405A1 (en) | Antibodies binding to canine vascular endothelial growth factor and uses thereof in treating canine angiogenesis-related diseases | |
| TW202408575A (zh) | 奧布替尼與ｔａｆａｓｉｔａｍａｂ聯合用藥治療 |